$3.59
2.87% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$3.59
-1.09 23.29% 1M
-5.49 60.46% 6M
-6.54 64.56% YTD
-5.53 60.64% 1Y
-64.66 94.74% 3Y
-20.87 85.32% 5Y
-14.61 80.27% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.10 2.87%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $296.09m
Enterprise Value $55.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.83
P/S ratio (TTM) P/S ratio 4.42
P/B ratio (TTM) P/B ratio 1.28
Revenue growth (TTM) Revenue growth 247.03%
Revenue (TTM) Revenue $67.03m
EBIT (operating result TTM) EBIT $-213.02m
Free Cash Flow (TTM) Free Cash Flow $-171.54m
Cash position $279.11m
EPS (TTM) EPS $-2.36
P/E forward negative
P/S forward 11.61
EV/Sales forward 2.18
Short interest 25.95%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

9x Buy
50%
9x Hold
50%

Analyst Opinions

18 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
67 67
247% 247%
100%
- Direct Costs 5.81 5.81
7% 7%
9%
61 61
369% 369%
91%
- Selling and Administrative Expenses 61 61
10% 10%
91%
- Research and Development Expense 207 207
34% 34%
309%
-207 -207
1% 1%
-309%
- Depreciation and Amortization 5.81 5.81
7% 7%
9%
EBIT (Operating Income) EBIT -213 -213
1% 1%
-318%
Net Profit -193 -193
6% 6%
-289%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Positive
24/7 Wall Street
one day ago
There has been a noticeable shift in the stock market over the last two months.
Neutral
Seeking Alpha
2 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo 2024 Healthcare Conference September 5, 2024 4:30 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Yanan Zhu - Wells Fargo Securities Yanan Zhu Let's get started. Thanks, everyone, for being here.
Neutral
Seeking Alpha
3 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O'Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today